Johnson & Johnson's (JNJ.US) oral IL-23R antagonist achieved positive top-line results in two Phase III studies

On November 18, Johnson & Johnson (JNJ.US) announced positive key results from its Phase III ICONIC-LEAD study of Icotrokinra (JNJ-2113), an oral IL-23R antagonist, in the treatment of plaque psoriasis (PsO). This is the first oral IL-23R-targeted drug to successfully complete a Phase III study.